Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bioxcel Therapeutics Inc.

1.91
-0.0300-1.55%
Post-market: 1.950.0400+2.09%19:58 EDT
Volume:176.21K
Turnover:338.58K
Market Cap:11.57M
PE:-0.16
High:2.00
Open:1.94
Low:1.87
Close:1.94
Loading ...

Lucid reiterates Buy on BioXcel after patent application approval

TIPRANKS
·
15 Jul

BioXcel Therapeutics Announces Allowance of U.S. Patent Application for Igalmi Dosing Regimen in Treating Acute Agitation

Reuters
·
15 Jul

BUZZ-U.S. STOCKS ON THE MOVE-Energy stocks, Apple, Vertex

Reuters
·
02 Jul

BioXcel Therapeutics' Shares Rise 6.4% on Positive Schizophrenia Drug Trial Recommendation

THOMSON REUTERS
·
01 Jul

BUZZ-U.S. STOCKS ON THE MOVE-NIP Group, Hyatt, BioXcel Therapeutics

Reuters
·
01 Jul

BioXcel Therapeutics' Shares Rise 11.6% Premarket After Positive Recommendation for Schizophrenia-Related Agitation Drug Trial

THOMSON REUTERS
·
01 Jul

BRIEF-Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia

Reuters
·
01 Jul

BioXcel Therapeutics Inc - Dsmb Recommends Continuation of Serenity at-Home Trial

THOMSON REUTERS
·
01 Jul

BioXcel Therapeutics Inc - Topline Data for Serenity at-Home Trial Expected in Q3 2025

THOMSON REUTERS
·
01 Jul

BioXcel Therapeutics Receives Second Positive Recommendation From Data Safety Monitoring Board (Dsmb) to Continue Serenity at-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated With Bipolar Disorders or Schizophrenia

THOMSON REUTERS
·
01 Jul

BioXcel Therapeutics initiated with a Buy at Lucid Capital

TIPRANKS
·
25 Jun

BioXcel Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $8 From $3

THOMSON REUTERS
·
23 Jun

BioXcel Therapeutics Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) to Continue Serenity at-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated With Bipolar Disorders or Schizophrenia

THOMSON REUTERS
·
27 May

BioXcel granted extension to regain compliance with Nasdaq listing requirement

TIPRANKS
·
27 May

BioXcel Therapeutics Granted Extension to Regain Compliance With Nasdaq Continued Listing Requirement

THOMSON REUTERS
·
27 May

BioXcel Therapeutics Inc expected to post a loss of $6.66 a share - Earnings Preview

Reuters
·
05 May

BRIEF-Bioxcel Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $8.1 Million From Time To Time Through Canaccord - SEC Filing

Reuters
·
04 Apr

BioXcel Therapeutics Inc: May Offer and Sell Shares of Common Stock of up to $8.1 Mln From Time to Time Through Canaccord - SEC Filing

THOMSON REUTERS
·
04 Apr

Bank of America Securities Keeps Their Sell Rating on Bioxcel Therapeutics (BTAI)

TIPRANKS
·
28 Mar

BioXcel Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Mar